Latest DRC News
![W. Timothy Garvey, M.D.](/shp/drc/images/News/rep_garvey_450px.jpg)
- Details
W. Timothy Garvey, M.D., a professor at the University of Alabama at Birmingham, was awarded the Gerald Reaven Distinguished Leader in Insulin Resistance Award by the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease. Garvey, known for developing Cardiometabolic Disease Staging, helps clinicians assess risk for Type 2 diabetes and cardiovascular disease, guiding treatment and weight loss therapy decisions.
![Timothy Garvey, M.D.](/shp/drc/images/News/rep_garvey_450px.jpg)
- Details
W. Timothy Garvey, M.D., a professor at the University of Alabama at Birmingham, recently contributed to a groundbreaking global commission that called for a major overhaul of obesity diagnoses, recommending a shift away from relying solely on body mass index, or BMI, to more accurately define obesity as a disease.
![Dr. Garvey receiving award](/shp/drc/images/News/Garvey-Reaven-010.png)
- Details
W. Timothy Garvey, M.D., FACE, MABOM, Charles E. Butterworth, Jr., Professor of Medicine and University Professor in the Department of Nutrition Sciences at the University of Alabama at Birmingham, was given the Gerald Reaven Distinguished Leader in Insulin Resistance Award by the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC).
![veggies](/shp/drc/images/News/Stream_veggies.png)
- Details
New research from the University of Alabama at Birmingham, published in the Journal of Clinical Endocrinology & Metabolism, shows that adults with Type 2 diabetes who follow a low-carbohydrate diet might experience improvements in their beta-cell function, potentially helping them manage their condition more effectively and potentially reduce or eliminate the need for medication.
![Blood Sugar](/shp/drc/images/News/Stream_blood_sugar.png)
- Details
While diabetes patients are categorized into two groups, either Type 1 or Type 2, no two patients are the same. The simple categorization often does not portray the disease and its many presentations, especially within different populations. For this reason, diabetes researchers and clinicians have emphasized the importance of growing the understanding of diabetes subtypes.
![Anath Shalev, M.D.](/shp/drc/images/News/anath-shalev-L.jpg)
- Details
The University of Alabama at Birmingham startup TIXiMED, Inc., has obtained clearance from the United States Food and Drug Administration to proceed to clinical trials under an Investigational New Drug for TIX100, its novel oral Type 1 diabetes drug. This represents a major milestone in the development of this new approach to T1D treatment and gives TIXiMED the green light to start human studies with TIX100.
![Timothy Garvey, M.D.](/shp/drc/images/News/rep_garvey_450px.jpg)
- Details
UAB Comprehensive Diabetes Center (UCDC) Associate Director W. Timothy Garvey, M.D., and collaborators recently published “Cardiometabolic Disease Staging and Major Adverse Cardiovascular Event Prediction in 2 Prospective Cohorts” in the journal JACC: Advances.
![W. Timothy Garvey, M.D., and Andrea Cherrington, M.D.](/shp/drc/images/News/Garvey_and_Cherrignton_Stream.jpg)
- Details
University of Alabama at Birmingham researchers recently presented NIH-funded findings regarding differences in medication acceptance, quality of life, insulin secretion, mortality and other outcomes among four commonly used Type 2 diabetes medications.
![Type 1 Diabetes](/shp/drc/images/News/Stream_type_1.png)
- Details
Researchers have discovered the novel mechanism that underlies a previously reported observation that infection by group A Streptococcus bacteria reduces the risk of later developing Type 1 diabetes.
![Fernando Ovalle, M.D.](/shp/drc/images/News/erep_dr_ovalle_550px_150dpi.jpg)
- Details
Usually, a diabetes diagnosis begins with a label: either Type 1 or Type 2 diabetes. Patients with diabetes are typically assigned one of these two labels and then treated accordingly.